Home › News › Industrial talks

Lupin?s Pithampur Unit-1 facility receives EIR from U.S. FDA

Lupin?s Pithampur Unit-1 facility receives EIR from U.S. FDA

Pharma major Lupin Limited (Lupin) today announced the receipt of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Pithampur Unit-1, India facility. The inspection for the facility was conducted by the U.S. FDA between February 3, 2020 and February 11, 2020 and concluded with two observations.

 

 

 

 

 

 

 

Commenting on the receipt of the EIR, Nilesh Gupta, Managing Director, Lupin said, “We are very happy to have received the EIR for our Pithampur Unit-1 facility with Voluntary Action Indicated (VAI) status. Continuous improvement of our quality and compliance standards across all our manufacturing sites is a key focus area for the company and we are committed to work with the U.S. FDA to manufacture and supply products of the highest quality from all our manufacturing sites.”

 

 

 

 

 

 

 

Lupin?s Pithampur Unit-1 facility receives EIR from U.S. FDA

Darshana

  • Info 1
  • Info 2
  • Info 3
More news about: industrial talks | Published by Darshana | April - 30 - 2020 | 107

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology